



Our Vision

To improve patient outcomes by making every breath count and to become the industry leader by 2020



Supported by the European Union's Horizon 2020 research and innovation programme under grant agreement No 711269



PMD Solutions

Novel Technology at the core

A brand new approach to Respiratory Effort Monitoring - a significant engineering challenge

Measuring the most sensitive indicator to well-being Breathing: Respiratory Effort is a total system indicator of wellness offering up to 48 hours early indication of sickness

Ongoing research & development into preventative monitoring & diagnostic technologies

Making every breath count by developing real time breath by breath monitoring - a true industry leader in this field



Ongoing excellence in clinical and applied research

Constant clinical investigation to prove the effectiveness of our technology

Global focus with an international presence

Genuine concern over patient's outcome in acute care together with international partners



Impact to European Society

- People are living longer
- COPD (respiratory diseases) 3rd biggest killer by 2030
- Emergency and Urgent Care under severe pressure
- Disease states such as sleep disorders going undiagnosed for up to 2 years post symptoms being recognised

Preventative monitoring is key, early detection is vital

- Healthier living: More years and Better Life
- Better acute care management (Lower Event Rate)
- Reducing preventable comorbidities thus improve healthcare economics + Quality of Life



Changing the Status Quo

Establish recognition as industry leaders



Grow the market



Scale




Platform - 2 applications: 1 product

Presently both clinical applications use the same device



- · OTS tablet device
- Android
- Disposable single use sensor
- Respiratory rate trend monitoring
- Continuous monitoring 4 days battery



- · OTS mobile phone
- Android
- Zero patient engagement needed
- Cloud processing + report generation



RespiraSense



Why is RR important?

Continuous rate Monitoring allows;

- The first sign
 of abnormal
 breathing
- To trigger the earliest intervention
- Leading to

 ≥ better patient
 outcomes



RespiraSense





Incidence of Respiratory Compromise to Increase by 31% by 2020

- 7% General
 Ward & 11%
 Post-op
- Costing

 ≥ €18,000 per
 event
- Up to 7

 ≥ additional bed days
- RespiraSense can give >80% ROI by impacting 1 in 20 patients



Goldhill and colleagues reported that 21% of ward patients with a respiratory rate of 25-29 breaths/minute assessed by a critical care outreach service died in hospital

These patients could have been identified as high risk up to 24 hours before the event with a specificity of over 95%

Recent evidence suggests that an adult with a respiratory rate of over 20 breaths/minute is probably unwell, and an adult with a respiratory rate of over 24 breaths/minute is likely to be critically ill

In another study, just over half of all patients suffering a serious adverse event on the general wards (such as a cardiac arrest or ICU admission) had a respiratory rate greater than 24 breaths/minute

In 1993, Fieselmann and colleagues reported that a respiratory rate higher than **27 breaths/minute** was the **most important** predictor of **cardiac arrest** in hospital wards

Subbe and colleagues found that, in unstable patients, relative **changes in respiratory rate** were much **greater than changes in heart rate or systolic blood pressure**, and thus that the respiratory rate was likely to be a better means of discriminating between stable patients and patients at risk



Why Screen?

A simple and accurate event screener;

Can enable sleep service providers

With minimum increases in resources


To increase

their patient coverage

To identify and serve more apnoea suffers

Status Quo

Bands slip, leading to re-tests
Bands are uncomfortable



PMD is changing the Status Quo

- Bands replaced with simple adhesive RS sensor
- Chest & gut measurements+ Position + Activity



Consumer application potential for home screening



Clinical Evidence

Today, a validated technology



2016 Efficacy with all products



2017 Evaluation of Economic Impact to Healthcare



Market Presence









International Team - Objectives

- **a.)** Establish Commercial Pathway
- **b.)** Increase User Base
- **c.)** Retain Existing User Base
- d.) Network the Global User Base



H2020 – Only Opportunity for SME Funding

1 Year

3 Attempts

1st in Europe

Application 1 - build proposition: Investment Business Plan, If we got it what would we actually want to do

Application 2 – refine Excellence and Impact with latest company updates

Application 3 – Refine and refine implementation including partners for skill gaps, the right budget, the right Ambition

Be mindful, projects are reviewed by people

Speak the language


Tell the story

Excite them

Prove it



H2020 – An Element of Funding Strategy



PMD funded by Angles & H2020

The right

→ validated

proposition

Big ambition & clear plan to execute

H2020, one ⇒ option of many Leverage to raise→ Growth Capital from VC funds



Thank you for the opportunity to present our offering

Myles Murray
Managing Director & CEO
myles@pmd-solutions.com
Bishopstown House | Model Farm Road | Co. Cork | Ireland



Supported by the European Union's Horizon 2020 research and innovation programme under grant agreement No 711269